Case Report

Aftermath of Apixaban: Atypical Anticoagulation Aftereffect

Bhesh Karki, Louis Costanzo, Sameer Joshi, and Aleksey Fiksman

1Department of Internal Medicine, SUNY Downstate Health Sciences University, Brooklyn 11203, NY, USA
2Department of Internal Medicine, Trumbull Regional Medical Center, Warren 44483, OH, USA
3Brooklyn VA Medical Center, 800 Poly Pl, Brooklyn 11209, NY, USA

Correspondence should be addressed to Bhesh Karki; bhesh.karki@downstate.edu

Received 11 March 2022; Revised 9 September 2022; Accepted 10 October 2022; Published 22 October 2022

1. Introduction

The 2012 Chapel Hill Consensus Conference (CHCC) defines cutaneous small vessel vasculitis as a single-organ vasculitis that involves small arteries in the skin. [1] It is often referred to as hypersensitivity vasculitis or leukocytoclastic vasculitis (LCV) and is characterized with neutrophils as the major inflammatory infiltrate. Apixaban is a reversible and direct inhibitor of factor Xa. It is an uncommon cause of LCV. There have been very few reported cases of this unusual condition. [2–4] We report a case of an elderly male who presented with palpable purpura shortly after the initiation of apixaban for a DVT and was diagnosed with cutaneous leukocytoclastic vasculitis. This case thus draws attention to an uncommon, but potential adverse reaction of apixaban.

2. Case Description

A 72-year-old man with prostate cancer on androgen deprivation therapy (monthly leuprolide injections) and likely a provoked deep vein thrombosis (DVT) of the left lower extremity (diagnosed 12 days ago) secondary to the cancer presented to the emergency department with complaints of a rash on his bilateral lower legs which he noticed 1 week ago. He described the rash as red, non-pruritic, mildly painful, and raised. The rash started near his ankles and spread rapidly up his legs to his buttocks. He denied any fever, joint pain, abdominal pain, or changes in urinary habits. He denied any recent travel or experiencing this type of rash before.

His other past medical history included hypertension on losartan, type 2 diabetes on insulin, and chronic kidney disease. His only new medication was apixaban 5mg twice daily that he was taking for 12 days for the recently diagnosed DVT. He had completed a seven day course of 10mg of apixaban twice daily and was taking 5mg twice daily on the day of presentation. He had never taken any anticoagulant prior to this and had no known drug allergies or other recent medication changes.

On examination, his vitals and systemic exam were unremarkable. Skin exam revealed diffuse palpable tender nonblanching erythematous patches extending from the dorsum of both feet bilaterally to the thigh with few scattered lesions on the buttocks. A fundoscopic eye examination was unremarkable, and there were no other lesions noted on his body. An extensive laboratory workup was performed (see
Tables 1 and 2) and a chest X-ray was without any significant findings. The urinalysis results revealed specific gravity-1.011, blood cell-11/hpf, hyaline casts-3/hpf, and granular cast 1/hpf. Urine and blood cultures were without any growth.

Both rheumatology and dermatology were consulted, and a skin biopsy was recommended for further evaluation. The 3 skin punch biopsies obtained (2 from left lateral thigh and 1 from right lower extremity) revealed perivascular infiltration of neutrophils within vessels in the upper dermis with leukocytoclastia, or neutrophilic debris. A direct immunofluorescence study showed intense granular vessel wall staining with IgA consistent with leukocytoclastic vasculitis. Apixaban was discontinued on the day of admission, and he was anticoagulated with low-molecular-weight-heparin (lovenox). His other home medications including insulin were continued. His pain was managed with acetaminophen and moisturizer was applied to his legs bilaterally. Upon discharge, he was transitioned from lovenox to dabigatran. At his 2-week follow-up visit, he had minimal cutaneous involvement, but no discomfort. At 1-month follow-up, the skin lesions had greatly resolved with near complete resolution.

3. Discussion

The common etiologies of the palpable purpura like infectious (no signs of sepsis, normal leukocyte count, and negative blood culture), hematologic/coagulopathic (normal platelet, prothrombin time, and partial thromboplastin time), autoimmune/rheumatologic/systemic vasculitis (negative RF, anti-CCP, ANA, ANCA, normal urinary sediment, slightly elevated complement, and normal eosinophil) were ruled out. Although rare, LCV can present as an extraintestinal manifestation of ulcerative colitis, however, more than 2/3rd patients have active intestinal disease in the upper dermis with leukocytoclastia, or neutrophilic debris. A direct immunofluorescence study showed intense granular vessel wall staining with IgA consistent with leukocytoclastic vasculitis.

Apixaban was discontinued on the day of admission, and he was anticoagulated with low-molecular-weight-heparin (lovenox). His other home medications including insulin were continued. His pain was managed with acetaminophen and moisturizer was applied to his legs bilaterally. Upon discharge, he was transitioned from lovenox to dabigatran. At his 2-week follow-up visit, he had minimal cutaneous involvement, but no discomfort. At 1-month follow-up, the skin lesions had greatly resolved with near complete resolution.

| Lab test                      | Value   | Reference range |
|-------------------------------|---------|-----------------|
| White blood cell              | 6.2 K/uL| 4.5–11 K/uL     |
| Hemoglobin                    | 12.0 g/dL| 13–18 g/dL     |
| Platelet                      | 275 K/uL| 150–450 K/uL    |
| Urea nitrogen                 | 17 mg/dL| 6–22 mg/dL      |
| Creatinine                    | 1.7 mg/dL| 0.4–1.2 mg/dL  |
| Protein, total                | 6.3 g/dL| 6.4–8.2 mg/dL   |
| Albumin                       | 3.6 g/dL| 3.8–5.1 mg/dL   |
| Bilirubin, total              | 0.6 mg/dL| 0.1–1.2 mg/dL  |
| Alkaline phosphatase          | 82 U/L  | 42–121 U/L      |
| Aspartate transaminase        | 18 U/L  | 10–42 U/L       |
| Alanine transaminase          | 18 U/L  | 10–40 U/L       |
| Glomerular filtration rate    | 42 ml/min| ≥60 ml/min     |
| PT/PTT                        | 12.8 s  | 9.6–12.4 s/     |
| Erythrocyte sedimentation rate| 26.2 s  | 28–36.3 s       |
| C-reactive protein            | 0.74 mg/dL| 0–0.5 mg/dL   |
| Antistreptolysin O            | 22.9 IU/mL| 0–200 IU/mL     |

| Lab test                      | Value   | Reference range |
|-------------------------------|---------|-----------------|
| Hepatitis C ab                | Negative| Negative        |
| Rheumatoid factor             | <3.5 IU/mL| 0–39 IU/mL     |
| CCP antibodies IgG/IgA        | 5 units | 0–19 units      |
| Antinuclear antibodies        | Negative| <1 : 80         |
| Cytoplasmic ANCA              | <1:20 titer| <1:20          |
| Perinuclear ANCA              | <1:20 titer| <1:20          |
| Myeloperoxidase Ab            | <9 U/mL | 0.0–9 U/mL      |
| Proteinase-3 Ab               | <3.5 U/mL| 0.0–3.5 U/mL    |
| Atypical pANCA                | <1:20 titer| <1:20          |
| Complement C3                 | 231.8 mg/dL| 90–180 mg/dL  |
| Complement C4                 | 44.9 mg/dL| 9–36 mg/dL     |
| Cardiolipin IgM ab            | <9 U/mL | 0–12 U/mL       |
| Cardiolipin IgG ab            | <9 U/mL | 0–14 U/mL       |
| Cardiolipin IgA ab            | <9 U/mL | 0–11 U/mL       |
| Cryoglobulin                  | Not detected| None          |
| Beta-2 glycoprotein 1 IgG ab  | <9 units| 0–20 units      |
| Beta-2 glycoprotein 1 Ig M ab | 15 units| 0–25 units      |
| Beta-2 glycoprotein 1 Ig A ab | 15 units| 0–32 units      |

LCV to evolve into a systemic vasculitis, this is a rare complication. [16]

The literature related to apixaban-induced LCV reveals cases with comparable clinical presentations, histopathologic findings, and a relatively parallel clinical course with nearly identical outcomes. The onset of cutaneous symptoms has been previously documented in 10–28 days after initiating therapy with apixaban. [2–4] Our patient noticed symptoms after approximately 7 days of apixaban. The presentation of palpable purpuric lesions on the lower extremities and buttocks without any systemic involvement is like those seen in the prior cases. [2–4] Also, the major histologic finding in these cases is perivascular infiltration of neutrophils within vessels in the dermis with or without the immunoglobulin deposition. [2–4]
The treatment for LCV is mainly supportive, directed towards the underlying cause, and involves cessation of the offending agent. Steroids can be considered if the disease is severe, as reported in a patient who had complete resolution of symptoms after a 5-week oral prednisone course. In the prior cases, cessation of apixaban resulted in a fairly rapid resolution of symptoms (about 3–12 weeks) with a favorable outcome. To add to the literature, our patient underwent near complete resolution of symptoms at approximately 6 weeks.

A special mention is the possible cross-reactivity of direct oral anticoagulants (DOACs). Anis and Jandreau reported the persistence of rash in a protein C deficient patient when switching from apixaban to rivaroxaban; which eventually subsided within 24 hours of starting warfarin. Similarly, Isaq et al. reported a second episode of purpuric rash in a patient on apixaban, with the first episode of the similar rash while on rivaroxaban. Our patient was switched to a DOAC with a different mechanism: a direct thrombin inhibitor, dabigatran. It is important to consider the potentiality of toxicity when switching between DOACs; specifically, those with similar structures and mechanisms of action.

**Consent**

The patient has given permission to publish this case.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

All authors contributed by writing different sections of the manuscript.

**References**

[1] J. C. Jennette, “Overview of the 2012 revised international Chapel Hill Consensus conference nomenclature of vasculitides,” *Clinical and Experimental Nephrology*, vol. 17, no. 5, pp. 603–606, 2013.

[2] U. B. Nasir, A. Kumar, and A. Easwar, “Apixaban causing leukocytoclastic vasculitis,” *Journal of Allergy and Clinical Immunology: In Practice*, vol. 6, no. 5, pp. 1744–1745, 2018.

[3] J. Spears, D. A. Chetrit, S. Manthey, C. Lee, and Y. Al-Saiegh, “Apixaban as a rare cause of leukocytoclastic vasculitis,” *Case Reports in Rheumatology*, vol. 2020, Article ID 7234069, 3 pages, 2020.

[4] M. Khan, M. Y. Madi, and J. Rencic, “Apixaban-induced cutaneous leucocytoclastic vasculitis,” *BMJ Case Reports*, vol. 13, no. 8, Article ID e237043, 2020.

[5] I. Pantic, D. Jevtic, C. W. Nordstrom, C. Madrid, T. Milovanovic, and I. Duminic, “Clinical manifestations of leukocytoclastic vasculitis, treatment, and outcome in patients with ulcerative colitis: a systematic review of the literature,” *Journal of Clinical Medicine*, vol. 11, no. 3, p. 739, 2022.

[6] R. G. Micheletti and C. Pagnoux, “Management of cutaneous vasculitis,” *La Presse Médicale*, vol. 49, no. 3, Article ID 104033, 2020.

[7] D. Baigrie, A. Goyal, and J. S. Crane, “Leukocytoclastic vasculitis,” in *StatPearls. Treasure Island (FL)* StatPearls Publishing, Tampa, FL, USA, 2022.
[8] A. V. Marzano, P. Vezzoli, and E. Berti, “Skin involvement in cutaneous and systemic vasculitis,” *Autoimmunity Reviews*, vol. 12, no. 4, pp. 467–476, 2013.

[9] S. Mukherjee, N. Era, M. Mukherjee, and S. K. Tripathi, “Leukocytoclastic vasculitis secondary to clozapine,” *Indian Journal of Psychiatry*, vol. 61, no. 1, pp. 94–96, 2019.

[10] J. A. Zadroga, V. Mogulla, C. Grant, D. Jevtic, A. Virata, and I. Dumic, “The many faces of purpura: vancomycin-induced leukocytoclastic vasculitis,” *Case Reports in Infectious Diseases*, vol. 2021, Article ID 9932425, 4 pages, 2021.

[11] Y. Garg, S. Jain, and A. Kumar, “A rare case of clomiphene-induced leukocytoclastic vasculitis,” *Journal of Basic and Clinical Physiology and Pharmacology*, vol. 30, no. 4, p. 30, 2019.

[12] N. B. Hasbal, T. Baştürk, Y. Koç, T. Sahutoğlu, F. Bayrakdar Çağlayan, and A. Ünsal, “Leukocytoclastic vasculitis associated with a new anticoagulant: rivaroxaban,” *Turkish Journal of Hematology*, vol. 34, no. 1, pp. 116-117, 2017 Mar.

[13] C. Y. Hsu, W. S. Chen, and S. H. Sung, “Warfarin-induced leukocytoclastic vasculitis: a case report and review of literature,” *Internal Medicine*, vol. 51, no. 6, pp. 601–606, 2012.

[14] B. Gerceker Turk, T. Dereli, D. Dereli, and T. Akalin, “Leuprolide acetate-induced leukocytoclastic vasculitis,” *Acta Obstetrica et Gynecologica Scandinavica*, vol. 86, no. 7, pp. 892-893, 2007.

[15] J. A. Carlson, “The histological assessment of cutaneous vasculitis,” *Histopathology*, vol. 56, no. 1, pp. 3–23, 2010.

[16] B. Morgado, C. Madeira, J. Pinto, and J. Pestana, “Leukocytoclastic vasculitis with systemic involvement associated with ciprofloxacin therapy: case report and review of the literature,” *Cureus*, vol. 8, no. 11, 2016.

[17] T. R. Anis and W. Jandreau, “Anti-xa inhibitor-induced hemorrhagic pruritic rash: a case report on possible cross-reactivity between apixaban and rivaroxaban,” *Clinical Pharmacology: Advances and Applications*, vol. 13, pp. 181–184, 2021.

[18] N. A. Isaq, W. M. Vinson, and S. Rahnama-Moghadam, “Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity,” *Dermatology Online Journal*, vol. 26, no. 10, Article ID 13030, 2020.